Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

被引：24

作者：

Pizzuti, Laura ^{[1
]}

Giordano, Antonio ^{[2
]}

Michelotti, Andrea ^{[3
]}

Mazzotta, Marco ^{[4
]}

Natoli, Clara ^{[5
]}

Gamucci, Teresa ^{[6
,7
]}

De Angelis, Claudia ^{[3
]}

Landucci, Elisabetta ^{[3
]}

Diodati, Lucrezia ^{[3
]}

Iezzi, Laura ^{[5
]}

Mentuccia, Lucia ^{[6
]}

Fabbri, Agnese ^{[8
]}

Barba, Maddalena ^{[1
]}

Sanguineti, Giuseppe ^{[9
]}

Marchetti, Paolo ^{[4
,10
]}

Tomao, Silverio ^{[11
]}

Mariani, Luciano ^{[12
]}

Paris, Ida ^{[13
]}

Lorusso, Vito ^{[14
]}

Vallarelli, Simona ^{[14
]}

Cassano, Alessandra ^{[15
]}

Airoldi, Francesca ^{[15
]}

Orlandi, Armando ^{[15
]}

Moscetti, Luca ^{[16
]}

Sergi, Domenico ^{[1
]}

Sarobba, Maria Giuseppina ^{[17
]}

Tonini, Giuseppe ^{[18
]}

Santini, Daniele ^{[18
]}

Sini, Valentina ^{[19
]}

Veltri, Enzo ^{[20
]}

Vaccaro, Angela ^{[5
]}

Ferrari, Laura ^{[5
]}

De Tursi, Michele ^{[4
]}

Tinari, Nicola ^{[4
]}

Grassadonia, Antonino ^{[4
]}

Greco, Filippo ^{[21
]}

Botticelli, Andrea ^{[2
]}

La Verde, Nicla ^{[22
]}

Zamagni, Claudio ^{[23
]}

Rubino, Daniela ^{[23
]}

Cortesi, Enrico ^{[24
]}

Magri, Valentina ^{[24
]}

Pomati, Giulia ^{[24
]}

Scagnoli, Simone ^{[24
]}

Capomolla, Elisabetta ^{[25
]}

Kayal, Ramy ^{[26
]}

Scinto, Angelo Fedele ^{[27
]}

Corsi, Domenico ^{[27
]}

Cazzaniga, Marina ^{[28
]}

Laudadio, Lucio ^{[29
]}

机构：

[1] IRCCS Regina Elena Natl Canc Inst, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy

[2] Sapienza Univ Rome, Azienda Osped St Andrea, Dept Clin & Mol Med, Rome, Italy

[3] Azienda Osped Univ Pisana, Dipartimento Oncol Dei Trapianti & Nuove Tecnol, UO Oncol Med I, Osped S Chiara, Pisa, Italy

[4] Ctr Sci Invecchiamento & Med Traslazionale CeSI M, Chieti, Italy

[5] Loc San Marciano Hosp, SS Trinita Hosp, Med Oncol Unit, Sora, Frosinone, Italy

[6] SS Trinita Hosp, Med Oncol Unit, Sora, Italy

[7] Sandro Pertini Hosp, Med Oncol, Rome, Italy

[8] Belcolle Hosp, Med Oncol Unit, Viterbo, Italy

[9] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[10] Sapienza Univ Rome, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[11] Univ Roma La Sapienza, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[12] IRCCS Regina Elena Natl Canc Inst, Dept Gynaecol Oncol, HPV Unit, Rome, Italy

[13] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy

[14] Giovanni Paolo II Hosp, IRCCS, Div Med Oncol, Bari, Italy

[15] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[16] Univ Hosp Modena, Dept Hematol & Oncol, Div Med Oncol, Modena, Italy

[17] Osped San Francesco, Div Med Oncol, Nuoro, Italy

[18] Univ Campus Biomed Rome, Dept Oncol, Rome, Italy

[19] Santo Spirito Hosp, Oncol Unit, ASL Roma 1, Rome, Italy

[20] Osped S Maria Goretti, Div Med Oncol, Latina, Italy

[21] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[22] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[23] St Orsola Marcello Malpighi Hosp, SSD Oncol Med Addarii, Bologna, Italy

[24] Univ Rome, Policlin Umberto I, Med Oncol, Rome, Italy

[25] Osped Parodi Delfino, Med Oncol, Colleferro, Italy

[26] IRCCS Regina Elena Natl Canc Inst, Dept Radiol, Rome, Italy

[27] Osped San Pietro Fatebenefratelli, Med Oncol Unit, Rome, Italy

[28] ASST Monza, Oncol Unit, Monza, Italy

[29] Osped Renzetti, Med Oncol, Lanciano, Italy

[30] Mater Salutis Hosp, ULSS21, Dept Pathol Surg & Oncol, Verona, Italy

[31] ASST Bergamo Ovest, Oncol Unit, Dept Oncol, Treviglio, Italy

[32] Regina Margherita Hosp, Med Oncol Unit, Rome, Italy

[33] Tor Vergata Univ Hosp, Tor Vergata Clin Ctr, Univ Hosp, Med Oncol Unit,Dept Syst Med, Rome, Italy

[34] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy

[35] Univ Aquila, S Salvatore Hosp, Med Oncol Dept, Laquila, Italy

[36] Univ Politecn Marche, Azienda Osped Univ Ospedali Riuniti Clin Oncol, Ancona, Italy

[37] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Rome, Italy

[38] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Via Elio Chianesi 53, I-00144 Rome, Italy

[39] IRCCS Regina Elena Natl Canc Inst, Sci Direct, Rome, Italy

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2019年 / 234卷 / 06期

关键词：

advanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world setting; 1ST-LINE TREATMENT; FULVESTRANT; COMBINATION; LETROZOLE; EFFICACY; SAFETY; MULTICENTER; ABEMACICLIB; PLACEBO; WOMEN;

D O I：

10.1002/jcp.27832

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6-35.4) and clinical benefit was 52.7% (95% CI, 48-57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8-16) and median overall survival was 24 months (95% CI, 17-30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2-, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

引用

页码：7708 / 7717

页数：10

共 50 条

[31] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
Leonardo Roberto da Silva
Camila Annicchino de Andrade
Fabrício Brenelli
Susana Ramalho
Tomás Reinert
Alessandra Borba Anton de Souza
Ana Elisa Ribeiro da Silva
Maria Beatriz de Paula Leite Kraft
Vivian Castro Antunes de Vasconcelos
Antônio Luiz Frasson
Renato Zochio Torresan
Cesar Cabello
Matthew J. Ellis
Luiz Carlos Zeferino
Breast Cancer Research and Treatment, 2021, 186 : 753 - 760
[32] Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
Demir, Atakan
Mandel, Nil Molinas
Paydas, Semra
Demir, Gokhan
Er, Ozlem
Turhal, Nazim Serdal
Bavbek, Sevil
Eralp, Yesim
Saip, Pinar Mualla
Guler, Emine Nilufer
Aydiner, Adnan
Uluc, Basak Oyan
Kilickap, Sadettin
Uskent, Necdet
Karadurmus, Nuri
Kaplan, Mehmet Ali
Yanmaz, Mustafa Teoman
Demir, Hacer
Alan, Ozkan
Korkmaz, Taner
Olgun, Polat
Uysal, Ozlem Sonmez
Altundag, Kadri
Gunduz, Seyda
Gunaldi, Meral
Sari, Murat
Beypinar, Ismail
Basaran, Gul
BALKAN MEDICAL JOURNAL, 2020, 37 (02) : 104 - 107
[33] Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting
Kimmick, G.
Pilehvari, A.
You, W.
Bonilla, G.
Anderson, R.
ANNALS OF ONCOLOGY, 2023, 34 : S373 - S373
[34] Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity
Frassoldati, Antonio
Biganzoli, Laura
Bordonaro, Roberto
Cinieri, Saverio
Conte, Pierfranco
De Laurentis, Michelino
Del Mastro, Lucia
Gori, Stefania
Lauria, Rossella
Marchetti, Paolo
Michelotti, Andrea
Montemurro, Filippo
Naso, Giuseppe
Pronzato, Paolo
Puglisi, Fabio
Tondini, Carlo Alberto
FUTURE ONCOLOGY, 2020, 16 (05) : 129 - 145
[35] Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
Martin, Miguel
Zielinski, Christoph
Ruiz-Borrego, Manuel
Carrasco, Eva
Ciruelos, Eva M.
Munoz, Montserrat
Bermejo, Begona
Margeli, Mireia
Csoszi, Tibor
Anton, Antonio
Turner, Nicholas
Casas, Maria, I
Morales, Serafin
Alba, Emilio
Calvo, Lourdes
De La Haba-Rodriguez, Juan
Ramos, Manuel
Murillo, Laura
Santaballa, Ana
Alonso-Romero, Jose L.
Sanchez-Rovira, Pedro
Corsaro, Massimo
Huang, Xin
Thallinger, Christiane
Kahan, Zsuzsanna
Gil-Gil, Miguel
EUROPEAN JOURNAL OF CANCER, 2022, 168 : 12 - 24
[36] Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
Agrawal, Chaturbhuj
Goyal, Pankaj
Agarwal, Amit
Tripathi, Rupal
Dodagoudar, Chandragouda
Baghmar, Saphalta
Sharma, Archana
Batra, Ullas
Talwar, Vineet
Goyal, Sumit
Kumar, Rajeev
Doval, Dinesh Chandra
SCIENTIFIC REPORTS, 2021, 11 (01)
[37] Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population
Chaturbhuj Agrawal
Pankaj Goyal
Amit Agarwal
Rupal Tripathi
Chandragouda Dodagoudar
Saphalta Baghmar
Archana Sharma
Ullas Batra
Vineet Talwar
Sumit Goyal
Rajeev Kumar
Dinesh Chandra Doval
Scientific Reports, 11
[38] Survival outcomes, multidimensional prediction and subsequent therapy in patients with hormone receptor-positive advanced breast cancer receiving palbociclib: a real-world analysis
Ma, Jiayi
Wu, Ziping
Xu, Yaqian
Wang, Yaohui
Lin, Yanping
Zhou, Liheng
Xu, Shuguang
Zhang, Jie
Yin, Wenjin
Lu, Jingsong
GLAND SURGERY, 2024, 13 (12)
[39] Chemotherapy or endocrine therapy, first-line treatment for patients with hormone receptor-positive HER2-negative metastatic breast cancer in China: a real-world study
Yuan, Yang
Zhang, Shaohua
Yan, Min
Yin, Yongmei
Song, Yuhua
Jiang, Zefei
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (10)
[40] Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor-positive, HER2-negative metastatic breast cancer: A real-world multicenter study
Li, Doudou
Jin, Yizi
Lin, Mingxi
Zeng, Cheng
Guo, Qing
Liu, Yanfei
Zhang, Jian
CANCER MEDICINE, 2024, 13 (04):

← 1 2 3 4 5 →